Healio

DecisionDx test can help identify sentinel lymph node risk

Please provide your email address to receive an email when new articles are posted on . Up to 88% of sentinel lymph node biopsies (SNLB) return with a negative result. The DecisionDx-Melanoma test, ...
Post Bulletin

Mayo Clinic Q&A: Advances in staging and surgical treatment of melanoma

I was just diagnosed with early-stage melanoma, and I am being referred to an oncologist. What happens next? Will I need a ...
Nasdaq

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...
Nasdaq

Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today ...
News Medical

New blood-based test detects lymph node metastasis in individuals with high-risk T1 colorectal cancer

Scientists at City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, have developed a novel, noninvasive liquid biopsy test for detecting lymph node ...
EurekAlert!

New genomic test could spare some people with melanoma from lymph node biopsy surgery

ROCHESTER, Minn. — A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes — a finding that could ...
Business Wire

New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from its prospective ...